Published in Arch Intern Med on November 10, 1997
Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest (2010) 1.18
Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) (2012) 0.82
Low-molecular-weight heparins in the treatment of venous thromboembolism. Curr Control Trials Cardiovasc Med (2000) 0.75
The importance of initial heparin treatment on long-term clinical outcomes. Arch Intern Med (1998) 0.75
Prospective study of the frequency and outcomes of patients with suspected pulmonary embolism administered heparin prior to confirmatory imaging. Thromb Res (2012) 0.75
Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study. Cardiovasc Ther (2009) 0.75
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood (1996) 7.31
Prevention of venous thromboembolism. Chest (2001) 5.59
Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med (1998) 3.70
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med (1992) 3.23
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med (2000) 2.82
Chronic idiopathic thrombocytopenic purpura. N Engl J Med (1994) 2.66
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med (2001) 2.37
Case-control study of prenatal ultrasonography exposure in children with delayed speech. CMAJ (1993) 2.31
Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med (1996) 2.24
Low-probability lung scan findings: a need for change. Ann Intern Med (1991) 2.22
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost (2014) 2.03
Pulmonary artery flow directed catheter: the evidence. Lancet (1996) 2.02
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest (1985) 1.92
The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med (1999) 1.80
Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med (2000) 1.72
Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest (1990) 1.65
Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA (1990) 1.55
A clinical study of the relationship between silicone breast implants and connective tissue disease. J Rheumatol (1998) 1.52
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med (1983) 1.51
Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med (1999) 1.50
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med (2000) 1.48
Ca2+-dependent hydrophobic-interaction chromatography. Isolation of a novel Ca2+-binding protein and protein kinase C from bovine brain. Biochem J (1984) 1.45
Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med (1994) 1.44
Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med (2000) 1.40
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med (2000) 1.34
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med (1997) 1.34
The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med (1973) 1.30
Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet (1992) 1.29
Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med (1992) 1.24
The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med (1998) 1.23
An alternative method for determination of the carpal height ratio. J Bone Joint Surg Am (1994) 1.22
Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery (1994) 1.22
A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med (1989) 1.21
Pulmonary embolism in outpatients with pleuritic chest pain. Arch Intern Med (1988) 1.14
Unexpected vitamin K deficiency in hospitalized patients. Can Med Assoc J (1973) 1.09
A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med (1994) 1.08
Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci (1974) 1.06
Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med (1998) 1.05
Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma. Br J Haematol (1970) 1.04
Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. N Engl J Med (1974) 1.02
The nature of experimental second-set kidney transplant rejection. 1. The role of coagulation in hyperacute (second-set) renal allotransplant rejection in dogs. Br J Exp Pathol (1970) 1.01
Prevalence and incidence of carpal tunnel syndrome in a meat packing plant. Occup Environ Med (1999) 1.01
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost (2007) 1.01
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med (2001) 1.00
The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation (1975) 0.99
Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med (1998) 0.97
Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am (1986) 0.96
Aging and heparin-related bleeding. Arch Intern Med (1996) 0.96
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br (2012) 0.96
Henoch-Schönlein purpura occurring in three members of a family. Can Med Assoc J (1973) 0.94
Influence of methodologic factors in a pooled analysis of 13 case-control studies of colorectal cancer and dietary fiber. Epidemiology (1994) 0.93
The diagnosis of clinically suspected venous thrombosis. Clin Chest Med (1984) 0.93
The low-probability lung scan. A need for change in nomenclature. Arch Intern Med (1995) 0.91
Serial impedance plethysmography in pregnant patients with clinically suspected deep-vein thrombosis. Clinical validity of negative findings. Ann Intern Med (1990) 0.91
Low molecular weight heparin treatment of venous thromboembolism. Prog Cardiovasc Dis (1994) 0.88
Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res (2001) 0.87
Thrombotic complications of antithrombotic therapy: a paradox with implications for clinical practice. Ann Intern Med (1997) 0.87
Idiopathic thrombocytopenic purpura: diagnosis and management. Am J Med Sci (1998) 0.86
Drug-induced thrombocytopenia. Curr Opin Hematol (1999) 0.86
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost (2013) 0.86
Therapeutic use of low-molecular-weight heparins. Haemostasis (1993) 0.85
Prophylaxis of venous thromboembolism. An overview. Chest (1986) 0.85
Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med (2000) 0.84
Calcineurin-mediated dephosphorylation of the human placental membrane receptor for epidermal growth factor urogastrone. Biochemistry (1985) 0.83
Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol (1986) 0.83
Preleukaemia and reticulocytosis: a case report with in vitro evidence for abnormal reticulocyte maturation. Scand J Haematol (1978) 0.83
Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med (1998) 0.83
Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost (1995) 0.82
Massive colchicine overdose: a report on the toxicity. Am J Med Sci (1976) 0.82
Different effects of heparin in males and females. Clin Invest Med (1998) 0.82
Von Willebrand's syndrome presenting as an acquired bleeding disorder in association with a monoclonal gammopathy. Blood (1973) 0.82
Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII. Br J Haematol (1973) 0.81
Disease-specific quality of life: the Gallstone Impact Checklist. Clin Invest Med (1996) 0.80
The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis (1998) 0.80